Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01023685 · ClinicalTrials.gov registry record · Phase 2
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01023685 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 24 participants.
The verdict
NCT01023685, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients.
Interventions
- BIOLOGICAL CAD106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01023685
The ClinicalTrials.gov registry entry for NCT01023685 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAD106 is the first listed.
NCT01023685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01023685 about?
NCT01023685 is a clinical study titled "To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients". This study will investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients.
What is the current status of trial NCT01023685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-12. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01023685?
The interventions under investigation include: CAD106 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01023685?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.